-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
So far, the new crown pandemic has affected the lives of millions of people around the world and has placed a huge burden on the global health system and economy.
Prevent COVID-19
The disease progression of severe COVID-19 is characterized by an increase in viremia in the initial stage, and then gradually disappear, followed by a second stage characterized by a sharp increase in systemic inflammation.
The increase in the levels of inflammatory cytokines and pro-inflammatory factors is related to the increase in disease severity and mortality.
Recently, researchers used multi-dimensional epigenetics, transcription, in vitro and in vivo analysis to report that the inhibition of topoisomerase 1 (TOP1) can alleviate the fatal inflammation induced by SARS-CoV-2 .
Inhibition of topoisomerase 1 (TOP1) can alleviate the fatal inflammation induced by SARS-CoV-2 .
Topotecan (TPT), an FDA- approved TOP1 inhibitor for treatment, was found to inhibit the inflammation induced by hamster infections .
Topotecan inhibits new crown-related inflammation
Topotecan inhibits new crown-related inflammationThese results support the potential of TOP1 inhibitors as an effective host-directed therapy against severe SARS-CoV-2 infection.
In addition, we also need to conduct clinical trials to evaluate the efficacy of reusing TOP1 inhibitors to treat COVID-19 in humans.
Original source:
Original source:Jessica Sook Yuin Ho et al.
Jessica Sook Yuin Ho et al.
Leave a message here
